Unadjusted comparisons of cardiovascular risk factors revealed frankly significant or borderline significant differences in AI (t = 2.576, p = 0.011), PWV (t = -1.53, p = 0.128), and mean maximum IMT (t = -1.40, p = 0.165) between AMD progressors and non-progressors (Table 3).
The χ tests for distribution showed no significant differences between cases and controls in most of the genotype frequencies except for borderline significant differences in CYP17 -34T>C (A1> A2) between cases and controls.
There was borderline significant difference in genotype distributions of SNP +190G/C between CHD cases and controls, but adjustment for the conventional risk factors such as age, sex, pack-year of smoking, drinking, activity, hypertension, DM, and family history of CHD yielded significant results (P = 0.012).
There was no significant difference in sorting time (ANOVA p = 0.42) and borderline significant difference in age (ANOVA, p = 0.057), which was due to a significant difference between opinion types I and IV (p = 0.04).
There were no significant differences in baseline characteristics between groups (Table 1), except for a borderline significant difference in diabetes social support (PL 4.0 vs. CHW 4.4, P = 0.053).
The only (borderline) significant difference in the laboratory test results was for serum alkaline phosphatase at day 42 and day 0, attributable to a significant decrease at 42 days in the placebo group (p = 0.03).
There was a borderline significant difference in the disabilities of arm, shoulder and hand (DASH) at one time point (12 months) in favour of the locking plate, but this was well below the minimum clinically important difference.
There was a borderline significant difference in E2 level (p = 0.05) between those who had taken their last tablet on the day of blood sampling (n = 17) and those who had taken their last tablet the day before (n = 11).
Three mutants showed decreased relative fitness compared to the wild type, with borderline significant difference in two, resulting in fitness order wild type>181C>K103N>V106M, whereas V106A mutant showed drastic decrease as almost non infectious.
When BMI z score over time was dichotomized as ≤0 or >0, there was a borderline significant difference in risk of islet autoimmunity between the two categories [χ(1) = 2.7, P = 0.09] (Table 2).
Per-protocol analysis (12 patients and 14 patients in the fluvoxamine and placebo group, respectively) of the same outcomes showed no significant differences except for a borderline significant difference in the general fatigue domain of the MFI in favour of the placebo group (p = 0.04).
